Macaque Target Validation for FDA-Approved Drugs

Evidence inventory of FDA-approved drugs whose development drew on macaque (cynomolgus/rhesus) pharmacology beyond GLP toxicology — target validation, functional PD, efficacy, or translational dose/PD data. Compiled in support of the argument that NHPs can supply a human-relevant target-validation layer that rodents often cannot (use case: paper, grant, investor deck, or company rationale).

Two user-pasted AI-generated reports (2026-09-12): a focused analysis of the strongest cases¹ and a systematic tiered catalogue.² Core claims were re-verified during ingest against FDA review PDFs and primary literature — see Verification & sources.

Evidence tiers (framework)

• Tier A — direct macaque efficacy / disease-model evidence: the drug altered a disease phenotype, pathological endpoint, or clinically meaningful physiological phenotype in macaques.
• Tier B — target-specific macaque pharmacology / PD: target engagement with a downstream biological effect demonstrated, but not the main disease-efficacy experiment.
• Tier C — NHP PK / safety / species relevance only: macaques were useful to development, but provide little basis for claiming that the macaque validated the therapeutic target.

The tier distinction is what makes the argument stronger than simply counting NHP studies.²

Systematic catalogue (Tier A/B/C)

Drug	FDA-approved target / mechanism	Disease / indication	Macaque species	What macaques contributed	Tier
Nemolizumab (NEMLUVIO)	IL-31RA	Atopic dermatitis; prurigo nodularis	Cynomolgus	IL-31 produced an itch phenotype; nemolizumab inhibited IL-31-driven scratching in vivo	A
Mepolizumab (NUCALA)	IL-5	Eosinophilic asthma; eosinophilic diseases	Cynomolgus	Reduced circulating eosinophils and pulmonary eosinophilia in an Ascaris-induced asthma model	A
Tocilizumab (ACTEMRA)	IL-6R	Rheumatoid arthritis and other inflammatory disease	Cynomolgus	Pharmacologically relevant primate inflammatory/arthritis studies; demonstrated consequences of IL-6R blockade	A
Denosumab (PROLIA/XGEVA)	RANKL	Osteoporosis; skeletal disease	Cynomolgus	Ovariectomized monkeys: reduced bone turnover, increased BMD and bone strength; model closely recapitulated postmenopausal bone loss	A
Romosozumab (EVENITY)	Sclerostin	Osteoporosis	Cynomolgus	Ovariectomized monkeys showed large increases in BMD, bone formation and bone strength; additional fracture/healing model	A
Ranibizumab (LUCENTIS)	VEGF-A	Neovascular AMD and retinal vascular disease	Cynomolgus	Laser-induced CNV model: reduced CNV development and vascular permeability	A
Aflibercept (EYLEA)	VEGF-A / VEGF trap	Neovascular AMD etc.	Cynomolgus	Laser-induced CNV: reduced lesion severity/leakage and demonstrated activity against established lesions	A
Faricimab (VABYSMO)	VEGF-A + Ang-2	Retinal vascular disease	Cynomolgus	Laser-induced CNV; reduced lesion severity, with evidence supporting the added Ang-2 mechanism	A/B
Raxibacumab (ABthrax)	Anthrax protective antigen (PA)	Inhalational anthrax	Cynomolgus	FDA Animal Rule pivotal efficacy studies; 40 mg/kg produced 69% 28-day survival vs 0% placebo	A
Tecovirimat (TPOXX)	Orthopoxvirus VP37/F13L	Smallpox	Cynomolgus	Four pivotal NHP/monkeypox efficacy studies; significant survival benefit and dose/duration optimization	A
Remdesivir (VEKLURY)	Viral RNA-dependent RNA polymerase	COVID-19	Rhesus	SARS-CoV-2 macaques showed reduced clinical disease, lung pathology and lung viral burden	A
Cabotegravir (VOCABRIA/CABENUVA/APRETUDE)	HIV integrase	HIV treatment/prevention	Rhesus/pigtail	Multiple macaque SHIV/SIV studies demonstrated strong protection at clinically relevant exposure and supported long-acting PrEP development	A
Benralizumab (FASENRA)	IL-5Rα	Eosinophilic asthma	Cynomolgus	Species-relevant receptor binding and profound depletion/suppression of eosinophils and precursors	B+
Erenumab (AIMOVIG)	CGRP receptor	Migraine	Cynomolgus	Inhibition of capsaicin-induced dermal vasodilation, a functional readout of CGRP-receptor blockade	B
Fremanezumab (AJOVY)	CGRP	Migraine	Cynomolgus	Demonstrated inhibition of CGRP-mediated/neurogenic vasodilation	B
Galcanezumab (EMGALITY)	CGRP	Migraine	Cynomolgus	~86% inhibition of capsaicin-induced dermal blood flow at 5 mg/kg IV (87/71/63% on Days 1/15/29)	B
Eptinezumab (VYEPTI)	CGRP	Migraine	Cynomolgus	Functional NHP assays demonstrated inhibition of CGRP-mediated vasodilation	B
Inclisiran (LEQVIO)	PCSK9 mRNA	Hypercholesterolemia / ASCVD	Cynomolgus	Reduced circulating PCSK9, with correlated sustained LDL-C and total-cholesterol reductions	B+
Ocrelizumab (OCREVUS)	CD20	Multiple sclerosis	Cynomolgus	Relevant NHP species; rapid depletion of CD20+ B cells to near-undetectable levels	B
Ofatumumab (KESIMPTA/ARZERRA)	CD20	CLL / MS	Cynomolgus	Dose-dependent and prolonged B-cell depletion; clear target-mediated PD	B
Golimumab (SIMPONI)	TNF-α	RA/PsA/AS/UC	Cynomolgus	Cynomolgus TNF was pharmacologically neutralized; macaque was selected as the pharmacologically relevant species	B/C
Sutimlimab (ENJAYVO)	C1s	Cold agglutinin disease	Cynomolgus	Near-complete inhibition of classical complement pathway activity, sustained over repeated dosing	B
Pegcetacoplan (EMPAVELI/SYFOVRE)	C3	PNH; geographic atrophy etc.	Cynomolgus	Monkey was the principal pharmacologically relevant species; inhibited human and cynomolgus complement	B/C
Polatuzumab vedotin (POLIVY)	CD79b	DLBCL	Cynomolgus	Human drug did not adequately cross-react; a cynomolgus-CD79b surrogate ADC was used to demonstrate target-mediated primate pharmacology	B−
Nivolumab (OPDIVO)	PD-1	Cancer	Cynomolgus	Demonstrated species-relevant PD/immunological effects, including altered T-cell phenotypes; tumor efficacy required other models	B
Pembrolizumab (KEYTRUDA)	PD-1	Cancer	Cynomolgus	High-affinity binding and target inhibition in monkey; pharmacodynamic saturation demonstrated in repeat-dose studies	B
Tafasitamab (MONJUVI)	CD19	DLBCL	Cynomolgus/rhesus	Relevant primate binding/cross-reactivity and safety pharmacology; no direct primate tumor efficacy model	C/B−
Guselkumab (TREMFYA)	IL-23p19	Psoriasis etc.	Cynomolgus	Important species for chronic safety and pharmacology assessment, but no compelling primate efficacy demonstration	C
Brolucizumab (BEOVU)	VEGF-A	Neovascular AMD	Cynomolgus	Extensive ocular PK and repeat-dose ocular toxicity studies; the key efficacy evidence was not a macaque efficacy model	C
Adalimumab (HUMIRA)	TNF-α	RA/IBD/PsA etc.	Cynomolgus	Developmental/reproductive studies; macaques demonstrated safety rather than target efficacy	C
Certolizumab pegol (CIMZIA)	TNF-α	RA/IBD/PsA	Cynomolgus	Pharmacokinetic and repeat-dose toxicology because of limited rodent cross-reactivity; no major macaque efficacy demonstration	C
Daratumumab (DARZALEX)	CD38	Multiple myeloma	Cynomolgus + chimpanzee	Important lesson: daratumumab did not bind cynomolgus/rhesus CD38; NHP studies therefore relied on surrogate material and were not target-validation experiments for the human drug	C
Lecanemab (LEQEMBI)	Aggregated Aβ	Alzheimer’s disease	Cynomolgus	Monkey PK supported development, but the disease-modifying efficacy evidence came principally from transgenic mouse models and clinical studies	C
Donanemab (KISUNLA)	Aβ-pE3	Alzheimer’s disease	Cynomolgus	Cynomolgus PK/safety; young monkeys were not expected to express the pharmacological target, making them unsuitable for efficacy	C
Aducanumab (ADUHELM)	Aggregated Aβ	Alzheimer’s disease	Cynomolgus	Extensive monkey PK/toxicology, but not a disease-efficacy validation model	C

Catalogue table preserved from the second report. The report text rounds the totals to “~32” with approximate class tallies; the table itself lists 35 rows.

Gold-standard cases

1. IL-31RA → nemolizumab — FDA states the antibody binds human and cynomolgus IL-31RA, blocks IL-31 signalling, and inhibits IL-31-induced itching in cynomolgus monkeys. Chain: human target → conserved primate target → target activation → disease-relevant behavioural phenotype → pharmacological reversal.
2. RANKL → denosumab — denosumab binds human/NHP RANKL but not rodent RANKL, so conventional rodent pharmacology could not substitute. The ovariectomized cynomolgus model (the only preclinical disease model used) produced a clinically meaningful osteoporosis phenotype: reduced bone turnover, increased BMD, preserved cortical/cancellous bone, increased bone strength — a complete target → mechanism → disease model → therapeutic phenotype chain.
3. Sclerostin → romosozumab — OVX cynos: BMD increased ~14–26% at lumbar spine and proximal femur (month 12) with corresponding strength gains; a separate monkey study used a critical bone-defect/fracture-repair paradigm. Primate bone architecture and biomechanics are far more human-like than most small-animal osteoporosis endpoints.
4. VEGF → ranibizumab / aflibercept / faricimab — the strongest entire therapeutic class: the cyno laser-CNV model is a biologically informative bridge (relevant tissue, vascular anatomy, disease phenotype), and faricimab’s review documents superiority over ranibizumab at an equimolar number of binding sites — not merely a convenient toxicity species.

CGRP class — target-class replication

Target	Approved drug	NHP functional assay
CGRP receptor	Erenumab	Capsaicin-induced dermal blood-flow inhibition
CGRP	Fremanezumab	Neurogenic/CGRP-mediated vasodilation inhibition
CGRP	Galcanezumab	~86% reduction of capsaicin-induced dermal blood flow
CGRP	Eptinezumab	Functional inhibition of CGRP-mediated vasodilation

Tier B (pathway pharmacology rather than a macaque migraine phenotype), but four independently developed approved drugs converging on the same NHP assay is a powerful class-level argument.

Animal Rule — NHP efficacy substitutes for human efficacy

• Raxibacumab (anthrax PA): cynos challenged with lethal aerosolized B. anthracis; 40 mg/kg → 28-day survival 9/13 (69%) vs 0/10 controls.
• Tecovirimat (orthopoxvirus VP37): approved under the Animal Rule; four NHP/monkeypox studies (dose, duration and delayed-treatment cohorts); resistance substitutions mapped to VP37 — genotype → target → drug resistance linked in the NHP model.
• Remdesivir (SARS-CoV-2 RdRp): all six treated rhesus showed reduced clinical signs and ~2.2 log10 lower lung viral RNA; caveat — the macaque disease model is milder and more acute than severe human COVID-19, a nuance that strengthens rather than weakens the general argument.
• Cabotegravir (HIV integrase): macaque SHIV/SIV transmission and challenge models demonstrated high protection at clinically achievable exposures and supported long-acting PrEP development — the advantage is modelling a complex viral transmission system in an intact primate immune system.

”Involved” without validation — boundary and negative cases

• Daratumumab (CD38) — bound human and chimpanzee CD38 but not cynomolgus/rhesus CD38; surrogate antibodies were required, so NHP studies were not target-validation experiments for the human drug.
• Donanemab (Aβ-pE3) — FDA notes the young monkeys used “would not be expected to express the pharmacological target” — a CNS example where macaques provide PK/safety but not target validation.
• Report-1 second tier (cyno cross-reactivity → PK/PD; decisive efficacy in rodent surrogates; report-level except tezepelumab): tezepelumab (TSLP — verified: mouse anti-TSLP surrogate), secukinumab/ixekizumab (IL-17A), guselkumab/tildrakizumab/risankizumab (IL-23p19), omalizumab (IgE — caution: direct cyno IgE pharmacology documented), liraglutide (GLP-1R), brolucizumab (VEGF-A).
• Counterexamples with insufficient cross-reactivity: eculizumab (C5), dupilumab (IL-4Rα) — surrogate approaches instead of direct macaque efficacy.

These negative controls prevent the argument from becoming “NHPs are always better”. The defensible claim: when the therapeutic target and disease biology are conserved in the primate, macaques can provide a level of target engagement, systems pharmacology and disease validation that cannot be obtained from standard rodent models.

Boundary cases — macaque evidence after the original approval

• Maraviroc / CCR5 — rhesus SHIV studies = prevention/microbicide development, not the original systemic-treatment package.
• Lenacapavir / HIV-1 capsid — pigtail macaque stHIV-A19 challenge: single 25 mg/kg SC dose protected all animals; later PrEP development.

What the systematic evidence says

Evidence class	~Examples	What it demonstrates
A — direct NHP efficacy	~12	Target manipulation changes a clinically relevant disease/pathophysiological phenotype
B — target-specific NHP PD	~14	Target engagement produces an integrated physiological/systemic response
C — PK/safety/species relevance only	~9	NHP was useful for development but does not establish target validity
Total identified	~35 rows	Curated, evidence-ranked dataset — not an exhaustive census

Per the report: do not quote the total as a final epidemiological statistic; treat it as a curated, evidence-ranked dataset. The strongest examples are not random — they cluster where rodents fail to reproduce the relevant human biology: human-specific biologics → immune targets → receptor pharmacology → vascular biology → bone biology → complex viral infection/transmission (IL-31/itch, IL-5/eosinophils, RANKL & sclerostin/bone, VEGF/retinal vasculature, CGRP/neurovascular, PCSK9/lipid metabolism, HIV/adaptive immunity, SARS-CoV-2/respiratory disease).

Ranking for an “NHP-enabled validation” argument (report 1)

1. VEGF-A → ranibizumab/aflibercept — primate disease phenotype ≈ clinical target
2. IL-31RA → nemolizumab — ligand → phenotype → blockade
3. IL-5 / IL-5Rα → mepolizumab/benralizumab — direct primate immunological pharmacology
4. CGRP → erenumab/fremanezumab/galcanezumab/eptinezumab — class-level convergence
5. IL-6R → tocilizumab — bona fide primate inflammatory disease model
6. PCSK9 → inclisiran — target → biomarker → phenotype bridge

Verification & sources

Verified against primary sources during ingest (all URLs resolve; key numbers checked at source):

• Nemolizumab — Oyama et al., Exp Dermatol 2018 (PMID 27714851): “suppressed […] for about 2 months”. Mepolizumab — Hart et al., JACI 2001 (PMID 11496242): reductions for 6 weeks
• Benralizumab — FDA BLA 761070 review: peripheral eosinophil + marrow precursor depletion. Tocilizumab — Uchiyama et al., Biol Pharm Bull 2008 (PMID 18520048): monkey CIA; ADA caveat corroborated
• Erenumab — FDA BLA 761077 review: dose-dependent DBF inhibition. Fremanezumab — BLA 761089: cyno capsaicin flare. Galcanezumab — BLA 761063: both “~86% at 5 mg/kg IV” (summary) and “87/71/63%, Days 1/15/29” (main text) retained. Eptinezumab — BLA 761119: cyno DBF
• Ranibizumab — Krzystolik et al., Arch Ophthalmol 2002 (PMID 11879138). Aflibercept — Nork et al., Arch Ophthalmol 2011 (PMID 21825187). Faricimab — Regula et al., EMBO Mol Med 2016 + FDA BLA 761235 review (equimolar: severity −0.99 vs −0.63 for ranibizumab, p<0.05)
• Inclisiran — FDA BLA 214012 + Lehoux et al., Pharmacol Res Perspect 2023 (DOI 10.1002/prp2.1080): PCSK9 ↓66–85%, LDL-C ↓65–92%
• Denosumab — JBMR literature (rodent RANKL non-binding; OVX cyno the only preclinical disease model); FDA BLA 125320 review exists (scanned). Romosozumab — Ominsky et al., J Bone Miner Res 2017 (PMID 27865001): “BMD was increased by 14% to 26% at the lumbar spine and proximal femur at month 12”
• Raxibacumab — FDA BLA 125349 summary review, verbatim: “28-day survival of 9/13 (69%) macaques compared to 0/10”. Tecovirimat — FDA NDA 208627 reviews: Animal Rule (21 CFR 314.610); four NHP/MPXV studies; delayed-treatment cohorts; VP37. Remdesivir — FDA NDA 214787 review: “2.2 log10 lower viral RNA levels in lung tissue”; primary study Williamson et al., Nature 2020 (PMID 32516797)
• Cabotegravir — SIV/SHIV macaque protection studies (PMC5263045); review PMID 26049951
• Daratumumab — FDA BLA 761036 review, verbatim: bound human/chimpanzee CD38, “not to CD38 from […] cynomolgus and rhesus monkey”. Donanemab — FDA BLA 761248 review, verbatim: “the young monkeys […] would not be expected to express the pharmacological target, AβN3pE-x”
• Polatuzumab vedotin — BJP 2019 (PMID 31270798): anti-cynomolgus CD79b surrogate ADC. Sutimlimab — FDA BLA 761164 review: “nearly complete inhibition of classical complement activity” in cyno. Ocrelizumab — FDA BLA 761053 review: cyno B-cell depletion
• Lenacapavir — Swanstrom et al., EBioMedicine 2023 (PMID 37625266)

Report-level rows not individually re-verified: ofatumumab, golimumab, pegcetacoplan (PharmR URL 404s), nivolumab, pembrolizumab, tafasitamab, guselkumab, adalimumab, certolizumab pegol, lecanemab, aducanumab. Additional flagged items: report-1’s “8 target/pathway classes” count is loose; tocilizumab and ranibizumab FDA PDFs are scanned images (claims verified via journal literature instead).

Open questions / next steps

• Systematic evidence matrix (report 2 proposal): columns = FDA drug, target, approval year, indication, macaque species, study design, n, endpoint, target cross-reactive?, contribution to dose selection?, macaque efficacy in approval package?, Animal Rule status, primary citation → enables computing the proportion of NHP-involved approvals where macaque data contributed target validation vs PK/PD vs safety only.
• CNS coverage remains the gap (report 1): the current set skews immunology, ophthalmology, bone, and antivirals; the CNS rows here (lecanemab, donanemab, aducanumab) are all Tier C — worth filling deliberately for the NHP-value argument.

Related pages

• preclinical-drug-screening — rodent-model preclinical drug development architecture (the contrast case)
• cebsit — primate neuroscience research context

Footnotes

1. raw/articles/fda-macaque-target-evidence-report-2026.md ↩

2. raw/articles/fda-macaque-evidence-catalogue-2026.md ↩ ↩²